|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 94 No. 3 (August 1), 1999:
pp. 902-908
Interleukin-12 Therapy of Cutaneous T-Cell Lymphoma Induces Lesion
Regression and Cytotoxic T-Cell Responses
Alain H. Rook,
Gary S. Wood,
Elisa K. Yoo,
Rosalie Elenitsas,
David M.F. Kao,
Matthew L. Sherman,
William K. Witmer,
Kenneth A. Rockwell,
Ryan B. Shane,
Stuart R. Lessin, and
Eric C. Vonderheid
From the Department of Dermatology, University of Pennsylvania School
of Medicine, Philadelphia, PA; the Department of Dermatology, Case
Western Reserve School of Medicine, Cleveland, OH; Genetics Institute,
Inc, Cambridge, MA; Investigational Pharmacy, Hospital of the
University of Pennsylvania, Philadelphia, PA; and the Department of
Dermatology, Allegheny University School of Medicine, Philadelphia, PA.
Progression of cutaneous T-cell lymphoma (CTCL) is associated with
profound defects in cell-mediated immunity and depressed production of
cytokines, which support cell-mediated immunity. Because we have
observed marked defects in interleukin-12 (IL-12) production in CTCL
and because IL-12 is critical for antitumor cytotoxic T-cell responses,
we initiated a phase I dose escalation trial with recombinant human
IL-12 (rhIL-12) where patients received either 50, 100, or 300 ng/kg
rhIL-12 twice weekly subcutaneously or intralesionally for up to 24 weeks. Ten patients were entered: 5 with extensive plaque, 3 with
Sezary syndrome, and 2 with extensive tumors with large cell
transformation. One patient with Sezary syndrome dropped out after 1 week for personal reasons. Subcutaneous dosing resulted in complete
responses (CR) in 2 of 5 plaque and partial responses (PR) in 2 of 5 plaque, and 1 of 2 Sezary syndrome (overall response rate
CR+PR 5 of 9, 56%). A minor response also occurred in 1 of 5 plaque patients. Intralesional dosing resulted in individual tumor
regression in 2 of 2 patients. Biopsy of regressing lesions showed a
significant decrease in the density of the infiltrate in all cases and
complete resolution of the infiltrate among those with clinical lesion
resolution. An increase in numbers of CD8-positive and/or
TIA-1-positive T cells were observed on
immunohistochemical analysis of skin biopsy specimens obtained from
regressing skin lesions. Adverse effects of rhIL-12 on this regimen
were minor and limited and included low-grade fever and headache. One
patient discontinued rhIL-12 at week 6 because of depression. These
results suggest that rhIL-12 may augment antitumor cytotoxic T-cell
responses and may represent a potent and well-tolerated therapeutic
agent for CTCL.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies
Mol. Cancer Ther.,
November 1, 2009;
8(11):
2983 - 2991.
|
|
|
|
|
|
|
E. Contassot, K. Kerl, S. Roques, R. Shane, O. Gaide, M. Dupuis, A. H. Rook, and L. E. French
Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in Sezary syndrome T-cells associated with impaired death receptor and FLICE-inhibitory protein expression
Blood,
May 1, 2008;
111(9):
4780 - 4787.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. M. Stanford, J. W. Barrett, P.-A. Gilbert, R. Bankert, and G. McFadden
Myxoma Virus Expressing Human Interleukin-12 Does Not Induce Myxomatosis in European Rabbits
J. Virol.,
November 15, 2007;
81(22):
12704 - 12708.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Del Vecchio, E. Bajetta, S. Canova, M. T. Lotze, A. Wesa, G. Parmiani, and A. Anichini
Interleukin-12: Biological Properties and Clinical Application
Clin. Cancer Res.,
August 15, 2007;
13(16):
4677 - 4685.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Siddiqui, C.-Y. Li, S. M. LaRue, J. M. Poulson, P. R. Avery, A. F. Pruitt, X. Zhang, R. L. Ullrich, D. E. Thrall, M. W. Dewhirst, et al.
A phase I trial of hyperthermia-induced interleukin-12 gene therapy in spontaneously arising feline soft tissue sarcomas
Mol. Cancer Ther.,
January 1, 2007;
6(1):
380 - 389.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Ansell, S. M. Geyer, M. J. Maurer, P. J. Kurtin, I. N.M. Micallef, P. Stella, P. Etzell, A. J. Novak, C. Erlichman, and T. E. Witzig
Randomized Phase II Study of Interleukin-12 in Combination with Rituximab in Previously Treated Non-Hodgkin's Lymphoma Patients.
Clin. Cancer Res.,
October 15, 2006;
12(20):
6056 - 6063.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. F. Little, J. M. Pluda, K. M. Wyvill, I. R. Rodriguez-Chavez, G. Tosato, A. T. Catanzaro, S. M. Steinberg, and R. Yarchoan
Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma
Blood,
June 15, 2006;
107(12):
4650 - 4657.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Nebozhyn, A. Loboda, L. Kari, A. H. Rook, E. C. Vonderheid, S. Lessin, C. Berger, R. Edelson, C. Nichols, M. Yousef, et al.
Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy
Blood,
April 15, 2006;
107(8):
3189 - 3196.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K.-i. Yamanaka, R. Clark, R. Dowgiert, D. Hurwitz, M. Shibata, B. E. Rich, K. Hirahara, D. A. Jones, S. Eapen, H. Mizutani, et al.
Expression of Interleukin-18 and Caspase-1 in Cutaneous T-Cell Lymphoma
Clin. Cancer Res.,
January 15, 2006;
12(2):
376 - 382.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Molina, J. Zain, D. A. Arber, M. Angelopolou, M. O'Donnell, J. Murata-Collins, S. J. Forman, and A. Nademanee
Durable Clinical, Cytogenetic, and Molecular Remissions After Allogeneic Hematopoietic Cell Transplantation for Refractory Sezary Syndrome and Mycosis Fungoides
J. Clin. Oncol.,
September 1, 2005;
23(25):
6163 - 6171.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. S. McGinnis, R. Ubriani, S. Newton, J. M. Junkins-Hopkins, C. C. Vittorio, E. J. Kim, M. Wysocka, and A. H. Rook
The Addition of Interferon Gamma to Oral Bexarotene Therapy With Photopheresis for Sezary Syndrome
Arch Dermatol,
September 1, 2005;
141(9):
1176 - 1178.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. E. French, B. Huard, M. Wysocka, R. Shane, E. Contassot, J.-F. Arrighi, V. Piguet, S. Calderara, and A. H. Rook
Impaired CD40L signaling is a cause of defective IL-12 and TNF-{alpha} production in Sezary syndrome: circumvention by hexameric soluble CD40L
Blood,
January 1, 2005;
105(1):
219 - 225.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Dummer, J. C. Hassel, F. Fellenberg, S. Eichmuller, T. Maier, P. Slos, B. Acres, P. Bleuzen, V. Bataille, P. Squiban, et al.
Adenovirus-mediated intralesional interferon-{gamma} gene transfer induces tumor regressions in cutaneous lymphomas
Blood,
September 15, 2004;
104(6):
1631 - 1638.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Tancrede-Bohin, M. A. Ionescu, P. de La Salmoniere, A. Dupuy, J. Rivet, M. Rybojad, L. Dubertret, H. Bachelez, C. Lebbe, and P. Morel
Prognostic Value of Blood Eosinophilia in Primary Cutaneous T-Cell Lymphomas
Arch Dermatol,
September 1, 2004;
140(9):
1057 - 1061.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Younes, B. Pro, M. J. Robertson, I. W. Flinn, J. E. Romaguera, F. Hagemeister, N. H. Dang, P. Fiumara, E. M. Loyer, F. F. Cabanillas, et al.
Phase II Clinical Trial of Interleukin-12 in Patients with Relapsed and Refractory Non-Hodgkin's Lymphoma and Hodgkin's Disease
Clin. Cancer Res.,
August 15, 2004;
10(16):
5432 - 5438.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Mitsuhashi, J. Liu, S. Cao, X. Shi, and X. Ma
Regulation of interleukin-12 gene expression and its anti-tumor activities by prostaglandin E2 derived from mammary carcinomas
J. Leukoc. Biol.,
August 1, 2004;
76(2):
322 - 332.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Shi, S. Cao, M. Mitsuhashi, Z. Xiang, and X. Ma
Genome-Wide Analysis of Molecular Changes in IL-12-Induced Control of Mammary Carcinoma via IFN-{gamma}-Independent Mechanisms
J. Immunol.,
April 1, 2004;
172(7):
4111 - 4122.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hisada, S. Kamiya, K. Fujita, M. L. Belladonna, T. Aoki, Y. Koyanagi, J. Mizuguchi, and T. Yoshimoto
Potent Antitumor Activity of Interleukin-27
Cancer Res.,
February 1, 2004;
64(3):
1152 - 1156.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Maier, A. Tun-Kyi, A. Tassis, K.-P. Jungius, G. Burg, R. Dummer, and F. O. Nestle
Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells
Blood,
October 1, 2003;
102(7):
2338 - 2344.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Kozar, R. Kaminski, T. Switaj, T. Oldak, E. Machaj, P. J. Wysocki, A. Mackiewicz, W. Lasek, M. Jakobisiak, and J. Golab
Interleukin 12-based Immunotherapy Improves the Antitumor Effectiveness of a Low-Dose 5-Aza-2'-Deoxycitidine Treatment in L1210 Leukemia and B16F10 Melanoma Models in Mice
Clin. Cancer Res.,
August 1, 2003;
9(8):
3124 - 3133.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Gollob, K. G. Veenstra, R. A. Parker, J. W. Mier, D. F. McDermott, D. Clancy, L. Tutin, H. Koon, and M. B. Atkins
Phase I Trial of Concurrent Twice-Weekly Recombinant Human Interleukin-12 Plus Low-Dose IL-2 in Patients With Melanoma or Renal Cell Carcinoma
J. Clin. Oncol.,
July 1, 2003;
21(13):
2564 - 2573.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Lenzi, M. Rosenblum, C. Verschraegen, A. P. Kudelka, J. J. Kavanagh, M. E. Hicks, E. A. Lang, M. A. Nash, L. B. Levy, M. E. Garcia, et al.
Phase I Study of Intraperitoneal Recombinant Human Interleukin 12 in Patients with Mullerian Carcinoma, Gastrointestinal Primary Malignancies, and Mesothelioma
Clin. Cancer Res.,
December 1, 2002;
8(12):
3686 - 3695.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Wysocka, M. H. Zaki, L. E. French, J. Chehimi, M. Shapiro, S. E. Everetts, K. S. McGinnis, L. Montaner, and A. H. Rook
Sezary syndrome patients demonstrate a defect in dendritic cell populations: effects of CD40 ligand and treatment with GM-CSF on dendritic cell numbers and the production of cytokines
Blood,
October 16, 2002;
100(9):
3287 - 3294.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Shi, A. L. Rakhmilevich, C. P. Heise, K. Oshikawa, P. M. Sondel, N.-S. Yang, and D. M. Mahvi
Intratumoral Injection of Interleukin-12 Plasmid DNA, Either Naked or in Complex with Cationic Lipid, Results in Similar Tumor Regression in a Murine Model
Mol. Cancer Ther.,
September 1, 2002;
1(11):
949 - 957.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Connors, E. D. Hsi, and F. M. Foss
Lymphoma of the Skin
Hematology,
January 1, 2002;
2002(1):
263 - 282.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S. M. Ansell, T. E. Witzig, P. J. Kurtin, J. A. Sloan, D. F. Jelinek, K. G. Howell, S. N. Markovic, T. M. Habermann, G. G. Klee, P. J. Atherton, et al.
Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma
Blood,
January 1, 2002;
99(1):
67 - 74.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. S. Wood
T-Cell Receptor and Immunoglobulin Gene Rearrangements in Diagnosing Skin Disease
Arch Dermatol,
November 1, 2001;
137(11):
1503 - 1506.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Vermeer, C. P. Tensen, P. M. van der Stoop, H. W. van Oostveen, M. Lund, R. J. Scheper, and R. Willemze
Absence of TH2 Cytokine Messenger RNA Expression in CD30-Negative Primary Cutaneous Large T-Cell Lymphomas
Arch Dermatol,
July 1, 2001;
137(7):
901 - 905.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Duvic, K. Hymes, P. Heald, D. Breneman, A. G. Martin, P. Myskowski, C. Crowley, and R. C. Yocum
Bexarotene Is Effective and Safe for Treatment of Refractory Advanced-Stage Cutaneous T-Cell Lymphoma: Multinational Phase II-III Trial Results
J. Clin. Oncol.,
May 1, 2001;
19(9):
2456 - 2471.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Duvic, A. G. Martin, Y. Kim, E. Olsen, G. S. Wood, C. A. Crowley, R. C. Yocum, and for the Worldwide Bexarotene Study Group
Phase 2 and 3 Clinical Trial of Oral Bexarotene (Targretin Capsules) for the Treatment of Refractory or Persistent Early-Stage Cutaneous T-Cell Lymphoma
Arch Dermatol,
May 1, 2001;
137(5):
581 - 593.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Poszepczynska, M. Bagot, H. Echchakir, D. Martinvalet, M. Ramez, D. Charue, L. Boumsell, and A. Bensussan
Functional characterization of an IL-7-dependent CD4+CD8alpha alpha + Th3-type malignant cell line derived from a patient with a cutaneous T-cell lymphoma
Blood,
August 1, 2000;
96(3):
1056 - 1063.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Mortarini, A. Borri, G. Tragni, I. Bersani, C. Vegetti, E. Bajetta, S. Pilotti, V. Cerundolo, and A. Anichini
Peripheral Burst of Tumor-specific Cytotoxic T Lymphocytes and Infiltration of Metastatic Lesions by Memory CD8+ T Cells in Melanoma Patients Receiving Interleukin 12
Cancer Res.,
July 1, 2000;
60(13):
3559 - 3568.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
R. Ohno, Y. Yamaguchi, T. Toge, T. Kinouchi, T. Kotake, M. Shibata, Y. Kiyohara, S. Ikeda, I. Fukui, A. Gohchi, et al.
A Dose-Escalation and Pharmacokinetic Study of Subcutaneously Administered Recombinant Human Interleukin 12 and Its Biological Effects in Japanese Patients with Advanced Malignancies
Clin. Cancer Res.,
July 1, 2000;
6(7):
2661 - 2669.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
J. A. Gollob, J. W. Mier, K. Veenstra, D. F. McDermott, D. Clancy, M. Clancy, and M. B. Atkins
Phase I Trial of Twice-Weekly Intravenous Interleukin 12 in Patients with Metastatic Renal Cell Cancer or Malignant Melanoma: Ability to Maintain IFN-{{gamma}} Induction Is Associated with Clinical Response
Clin. Cancer Res.,
May 1, 2000;
6(5):
1678 - 1692.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. C. Showe, F. E. Fox, D. Williams, K. Au, Z. Niu, and A. H. Rook
Depressed IL-12-Mediated Signal Transduction in T Cells from Patients with Sezary Syndrome Is Associated with the Absence of IL-12 Receptor {beta}2 mRNA and Highly Reduced Levels of STAT4
J. Immunol.,
October 1, 1999;
163(7):
4073 - 4079.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
